GlassScriptPhysician profile
Aymen Bukannan
NPI 1700179983
$5,937.64
in general payments reported to CMS, 2019-2025
17 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $212 · 2021: $17.80 · 2022: $2,801 · 2023: $2,198 · 2024: $314 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,461 · Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,460.86 |
| Food and Beverage | $1,197.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $3,796.62 | 2022-2023 | Single Use Electrosurgical Hemostatic Forceps, Single Use Electrosurgical Knife Kd-655 |
| Erbe USA INC | $350.67 | 2022-2025 | Erbe Vio3, Erbe, Vio Cryo Apc |
| Olympus America INC. | $350.57 | 2022-2023 | Evis Exera III Gastrointestinal Videoscope, Single Use Electrosurgical Knife Kd-655, Long Clip |
| Boston Scientific Corporation | $313.60 | 2020-2025 | Apollo Esg Nxt System |
| Endogastric Solutions, INC | $213.75 | 2022-2023 | Esophyx |
| Fujifilm Healthcare Americas Corporation | $175.03 | 2022-2023 | |
| Janssen Biotech, INC. | $127.08 | 2024 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $125.00 | 2019 | |
| Apollo Endosurgery US INC | $89.21 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Covidien LP | $87.26 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $83.22 | 2024 | Dat Device |
| Ironwood Pharmaceuticals, INC | $53.38 | 2019-2023 | Linzess |
| Lumendi LLC | $42.94 | 2023 | Dilumen Ez1, 130 Cm, Dilumen Ez1, 103 Cm |
| Abbvie INC. | $38.10 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $37.01 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aymen Bukannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.